Please login to the form below

Not currently logged in
Email:
Password:

Merck KGaA shakes up pharma leadership

Stefan Oschmann becomes deputy CEO as Belén Garijo assumes more responsibility

merck stefan oschmannMerck KGaA has made several changes to the leadership of its pharmaceutical business.

At the start of next year Stefan Oschmann (top right), current CEO for pharma, will move to a new role as deputy CEO of the entire group. He will also become vice chairman of the executive board.

Oschmann will be replaced by Belén Garijo (bottom right), current CEO of Merck's biotech division Merck Serono in a move that will expand her responsibilities, adding oversight for consumer health, allergy and biosimilars.

Johannes Baillou, chairman of the board of partners of Merck, said: “With today's management decisions we strengthen Merck's leadership team and prepare the ground for continuity to reach our ambitious growth targets until the year 2018 and beyond.”

Belén Garijo, Merck KGaAThe announced comes one year after Garijo left her role as Merck Serono's chief operating officer to replace Oschmann as CEO of the division.

Garijo's career prior to joining Merck in 2011 included a spell at Sanofi, where she led global integrations of the company's acquisition of Genzyme.

Oschmann also joined Merck in 2011, having spent the previous 11 years at its US-based namesake Merck & Co, known as MSD outside the US and Canada.

19th September 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics